CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

EZH2 phosphorylation by CDK2 promotes progression of triple-negative breast cancer (TNBC). Here, the authors show that this signaling axis downregulates ERα, and thus combinatorial blockade of CDK2 and EZH2 sensitizes TNBC cells to tamoxifen.

Guardado en:
Detalles Bibliográficos
Autores principales: Lei Nie, Yongkun Wei, Fei Zhang, Yi-Hsin Hsu, Li-Chuan Chan, Weiya Xia, Baozhen Ke, Cihui Zhu, Rong Deng, Jun Tang, Jun Yao, Yu-Yi Chu, Xixi Zhao, Ye Han, Junwei Hou, Longfei Huo, How-Wen Ko, Wan-Chi Lin, Hirohito Yamaguchi, Jung-Mao Hsu, Yi Yang, Dean N. Pan, Jennifer L. Hsu, Celina G. Kleer, Nancy E. Davidson, Gabriel N. Hortobagyi, Mien-Chie Hung
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/db070b7abc844972aa2cc8c48facb949
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:EZH2 phosphorylation by CDK2 promotes progression of triple-negative breast cancer (TNBC). Here, the authors show that this signaling axis downregulates ERα, and thus combinatorial blockade of CDK2 and EZH2 sensitizes TNBC cells to tamoxifen.

Ejemplares similares